Search
Dexamethasone Treatment Options
A collection of 1458 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
1393 - 1404 of 1458
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
Completed
The primary objective of this proposed research study is to evaluate the safety of intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to intravitreal ranibizumab alone in the treatment of wet ARMD. The addition of the broad spectrum anti-inflammatory activity of dexamethasone may augment the anti-VEGF activity of ranibizumab by amelioration of inflammation existing in the microenvironment of the choroidal neovascularization. While the anti-VEGF agents have prov... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/18/2012
Locations: Bay Area Retina Associates, Walnut Creek, California
Conditions: Exudative Age-Related Macular Degeneration
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
Completed
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/04/2012
Locations: Novartis Investigator Site, Birmingham, Alabama +3 locations
Conditions: Arthritis, Gouty
A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
Terminated
The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/03/2012
Locations: Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas
Conditions: Corneal Infiltrates
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Stanford University Medical Center, Palo Alto, California +7 locations
Conditions: Leukemia, Myelocytic, Acute
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
Completed
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population.
Combined modality therapy may prove of benefit for patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2012
Locations: San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California +6 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
Completed
The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2012
Locations: Northern California Retina Vitreous Associates, Mountain View, California
Conditions: Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Birmingham, Alabama +222 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
Completed
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2012
Locations: Not set, San Antonio, Texas +2 locations
Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
Terminated
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2012
Locations: Not set, Fort Myers, Florida +1 locations
Conditions: Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
Completed
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2012
Locations: Clinical Research Atlanta, Stockbridge, Georgia +5 locations
Conditions: Perennial Allergic Rhinitis
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
Completed
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. The current protocol will enroll patients with relapsed or refractory multiple myeloma requiring second or third line therapy. Six patients each will be treated with at one of 4 dose levels in a phase 1 study. All patients will receive perifosine, lenalidomide and dexamethasone of each 28 day cycle. The doses of perifosine and lenalidomide will be va... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2012
Locations: Not set, Ann Arbor, Michigan
Conditions: Multiple Myeloma
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
Completed
The purpose of this study is to evaluate the clinical efficacy and safety of Tobradex ST compared to AzaSite in the treatment of moderate to severe chronic blepharitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2012
Locations: Ora, Andover, Massachusetts
Conditions: Blepharitis
1393 - 1404 of 1458